Has Enfortumab been included in medical insurance when it is launched in China?

Enfortumab vedotin is a new type of targeted therapy for advanced or metastatic urothelial cancer (urothelial cancer). Although it has achieved certain progress and recognition internationally, as of now, ennosumab has not yet obtained marketing approval in China and has not yet been included in the scope of medical insurance reimbursement.

This means that patients in China currently cannot purchase ennozumab through formal channels. Therefore, some patients may need to purchase ennosumab through overseas channels, usually imported from countries such as Japan. However, this kind of cross-border purchase not only involves the price of drugs, but may also be restricted and affected by import, customs clearance and other processes, which increases the financial burden and inconvenience for patients.

Currently, in foreign markets, especially in Japan, enfortumab vedotin (Enfortumab vedotin) is usually sold as an original drug. According to current information, the price of ennosumab is approximately more than 10,000 yuan, but the specific price may fluctuate due to market supply and demand, exchange rates and other factors.

However, even abroad, the price of ennosumab is still relatively high, which may be a burden for many patients. Especially considering that patients with urothelial cancer often require long-term and ongoing treatment, which can put a huge financial strain on patients and their families.

Given that ennosumab, a new targeted therapy drug, has shown good efficacy in the treatment of patients with advanced urothelial cancer, it has brought a glimmer of hope. Therefore, there is an urgent need for the government, medical institutions, pharmaceutical companies and other parties to work together to speed up the marketing approval and medical insurance inclusion of ennozumab in China to ensure that patients can obtain and afford this important treatment drug in a timely manner.

At the same time, for patients who cannot wait for the domestic launch, supervision and guidance from relevant departments also need to be strengthened to ensure that they can safely and legally obtain ennosumab purchased through overseas channels, and to minimize the inconvenience and additional costs caused by cross-border purchases.